Orexin-B — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Orexin-B

Also known as: Hypocretin-2, OXB, Orexin B, HCRT2, Hypocretin 2, Prepro-orexin-derived peptide B

Endogenous hypothalamic neuropeptide / dual orexin receptor agonist / wakefulness and arousal promoter

Research chemicalLast updated: October 19, 2026Based on 13 peer-reviewed studies

What it is

Orexin-B is a wakefulness peptide produced in the brain that plays a central role in maintaining alertness and sleep-wake cycles. It is studied as a research tool and biomarker in narcolepsy and neurodegenerative disease. Not FDA-approved as a standalone therapy; drugs that block its receptor (daridorexant, suvorexant) are FDA-approved for insomnia.

The scientific side

Orexin-B (also known as Hypocretin-2) is a 28-amino-acid neuropeptide produced by a small population (~10,000–20,000) of neurons in the lateral hypothalamic area (LHA) and perifornical area. It is cleaved from the prepro-orexin precursor protein, which also yields Orexin-A (Hypocretin-1, 33 amino acids). Orexin-B is considered the phylogenetically ancestral form of the two orexin peptides, and OX2R (the orexin-2 receptor) is the prototype receptor conserved across all vertebrates. See also our page on Orexin A for the companion neuropeptide with distinct receptor selectivity. Orexin-B activates two G-protein-coupled receptors: OX1R (orexin-1 receptor) and OX2R (orexin-2 receptor). Orexin-B has approximately equal affinity for both receptors in most species, though OX2R is the primary receptor mediating its wakefulness-promoting effects. In contrast, Orexin-A has 10-fold higher affinity for OX1R vs. OX2R. Both receptors are Gq/11-coupled (and to a lesser extent Gs-coupled), with activation triggering PKC, ERK1/2, intracellular calcium release, and cAMP-dependent pathways depending on cell type. Orexinergic neurons project widely throughout the brain to monoaminergic nuclei (locus coeruleus/norepinephrine, dorsal raphe/serotonin, tuberomammillary nucleus/histamine), cholinergic basal forebrain, and brainstem reticular formation (PMID 28012091, PMID 39706239). These projections excite arousal-promoting neurons, stabilizing the wake state and preventing inappropriate state transitions. Selective loss of orexin neurons causes narcolepsy type 1 — characterized by excessive daytime sleepiness and cataplexy — demonstrating that the orexin system is non-redundant for normal wakefulness maintenance. Beyond wakefulness, Orexin-B and OX2R are expressed in reproductive tissues including epididymal epithelium, suggesting local paracrine roles in reproductive function. In the retina, Orexin-B suppresses GABAC-mediated inhibitory currents in rod bipolar cells via OX1R and OX2R, potentially enhancing visual signal-to-noise during the active (wake) phase. Orexin-B projections also innervate the superior salivatory nucleus, implicating the system in autonomic control of salivary secretion. Regarding addiction, orexin neurons become activated by drug-associated cues and drive goal-directed drug-seeking behavior through OX1R and OX2R in cortical and subcortical circuits.

Class: Endogenous hypothalamic neuropeptide / dual orexin receptor agonist / wakefulness and arousal promoter

Administration & storage

Administration
Intravitreal injection — retinal study in rats (PMID: 29325900)Intracerebroventricular injection — referenced in review literature for mechanistic studies (PMID: 28012091)
Storage
No storage data described in reviewed abstracts. Standard peptide storage: lyophilized at -20°C; reconstituted solutions at 4°C short-term.
Cautions
No human safety data exists for exogenous Orexin-B administration. All in vivo data are from animal studies.,The orexin system is deeply involved in arousal, reward, and addiction mechanisms; pharmacological manipulation could produce unexpected effects on sleep-wake cycles and reward pathways.,OX2R agonists (drugs that mimic Orexin-B's primary signaling pathway) are in active clinical trials for narcolepsy — indicating potential wakefulness-promoting effects that require medical supervision.,Poor blood-brain barrier penetration of native orexin peptides limits peripheral bioavailability; central effects require direct CNS delivery in animal research, which is not feasible in community settings.

Legal & regulatory status

US FDA

Not approved by the US FDA for any therapeutic indication. Orexin receptor antagonists (suvorexant, lemborexant, daridorexant) are FDA-approved for insomnia, targeting the same system. Orexin receptor agonists…

WADA

Not stated in reviewed literature as explicitly prohibited. As a peptide with potential wakefulness-promoting effects, Orexin-B could fall under S6 Stimulants or other relevant categories; however, no specific orexin…

Health Canada

Not stated in reviewed literature as an approved therapeutic — requires manual verification. Suvorexant is approved in Canada for insomnia treatment.